||EPS - Basic
||Market Cap (m)
|Health Care Equipment & Services
Spire Health Share Discussion Threads
Showing 1951 to 1974 of 1975 messages
|MIDAS SHARE TIPS: Why cutting edge Spire Healthcare deserves a 'buy' treatment
Read more: hTTp://www.thisismoney.co.uk/money/investing/article-3839976/MIDAS-SHARE-TIPS-cutting-edge-Spire-Healthcare-deserves-buy-treatment.html#ixzz4NFzfpuSt
Follow us: @MailOnline on Twitter | DailyMail on Facebook
Around half the company’s business is still from medical insurance clients and about 30 per cent from the NHS. The latter rose at a healthy rate in the first half, boosted by NHS patients choosing to have their operations at Spire hospitals under the eReferral scheme.
Spire runs the UK’s second-biggest chain of private health facilities, with 39 hospitals and 13 clinics. It is investing £175million in further capacity, including new hospitals in Manchester and Nottingham in the coming months and about 20 new operating theatres.
Midas verdict: Spire is pushing the boundaries of consumer medical treatment with significant investment and the shadow of its major shareholder will help to underpin the price. Buy.|
|Mediclinic said to weigh £1.8 billion plus takeover bid for Spire Healthcare
Friday, 16 September 2016, 11:03 am
Mediclinic is preparing to bid for Spire Healthcare, the FTSE 250 company that was formed from the sale of BUPA hospitals.
According to excellent sources, Mediclinic is working with bankers from Morgan Stanley on the potential purchase of the remainder of Spire Healthcare that it doesn't own (remember last year Mediclinic bought 29.9pc of Spire Healthcare for 360p a share).
Now, to be clear I'm not the first financial journalist to raise the prospect of a Mediclinic bid for Spire Healthcare. In late August, several British stock market reporters picked up on a note from JP Morgan, which theorised that now might be the right time for FTSE 100-listed Mediclinic to buy the remainder of Spire given the currency fluctuations post the Brexit referendum. I have pasted the relevant paragraphs from the JP Morgan note below:
"In our view, the weakness in the GBP and strength of MDC’s share price vs Spire’s is an opportunity for MDC to consolidate its ownership of Spire (currently 29.9%). We estimate it could pay a 35% premium for Spire and see year one EPS increase by 3-4%, rising to 10% in year three assuming a debt-based deal. Alternatively, if MDC chose to raise equity ~£300m-500m (4-7%) in order to leave less gearing and also fund Spire’s London hospital expansion, year one accretion would drop to 2-1%. We note the authority to raise equity afforded Remgro, MDC’s largest shareholder (~44.6%), at its Aug-16th AGM."
But from what I understand from excellent sources is bankers from Morgan Stanley, Mediclinic's financial advisers, are actually working on the deal suggested by the JP Morgan analyst. One source reckons Mediclinic is just a few weeks away from submitting a formal approach for Spire. I don't have much more information than that but I have been told any offer is likely to be at about a 30pc premium to the current share price.
Mediclinic declined to comment. However, people familiar with the company tried to play down the tale, unsurprisingly.
- See more at: hxxp://www.betaville.co.uk/news/mediclinic-said-to-be-preparing-1.5-billion-plus-bid-for-spire-healthcare/#sthash.7inBYdLQ.dpuf|
|Mediclinic have come down from near 1100 to 927 recently and they hold 29.9% of Spire so it looks as if the market has really caught more than a sniff of a bid here.
Say thirty per cent premium on 360p as recently priced equals 468p (?).|
|Hopefully thats the case can only see the strikes being a good thing for spire in my view.|
|Do you think that the junior doctors strikes will result in considerable business for Spire's hospitals via self pay and NHS transfers ?|
|Mediclinic has 29.9% of Spire. Will they be tempted to bid for the balance after the fall in sterling ? What do the takeover rules say about how soon they can bid after buying the 29.9 % stake ?|
|Can't keep a quality stock down, looks poised for further gains after recent results.|
its the oxman
|wants to kiss 200p|
|Doesn't see like it|
|Is someone building up a stake in Spire??|
|Glad I got out first thing today|
Investec downgrades to a sell|
|Near 7 percent drop on no news ???|
|Any Chartists opinion on these would be great!|
|decent director buy at 306p and mediclinic involvement looks interesting|
|dipped my toe|
|It seems someone has been leaking news, that's why the share price starting dipping late last week.
Long-term these look a strong investment|
|Spire is one of the main tips in this weeks IC.
|Interesting but who would run a big group of hospitals>>>>>>>>>>>DOCTORS?????
That is the big block to these deals and that is why SPI is run not by doctors but professional managers of businesses.
Nevertheless the UK needs to support the NHS and private hospital groups especially as we all get older and its this segment who now has the disposal income to keep fit and well.........just go down to the Spire in Cambridge and see what I see most days and also look at where some of the patients come from.....Addenbrookes.|
|CapVest to sell stake in Mater
Investment firm CapVest is looking to exit its majority investment in Mater Private Healthcare early next year.
The Sunday Times has reported that CapVest is in the process of selecting a firm to run the sale process with Investec and Rothschild believed to be in the frame.
The move follows the collapse of a potential sale of Mater to South African hospital operator Netcare. It was reported that Netcare’s unsolicited offer valued Mater at €500 million (£367.8 million).
Furthermore, last year Capvest proposed a merger between Mater and Hermitage, another Irish private hospital but the talks fell through, as well.
There has been speculation that Netcare, Spire Healthcare and Mater’s management team will be potential bidders for the Irish hospital group.
CapVest acquired a 51% stake in the Mater Private Hospital Dublin in 2007, a deal which valued the hospital at €350 million.
The private hospital group then bought Cork Medical Centre for €90 million in 2011. In addition to the two hospitals, Mater now also operates two cancer centres in Limerick and Liverpool (as part of a joint venture with Clatterbridge Cancer Centre NHS Trust) and outpatient clinics in Drogheda, Navan and Sligo. The company provides healthcare for members of the Dubai Police Force and their families too.
Mater has annual revenues of €200 million|
|Woodford and his gang have topped up to with the new SA shareholder they control over 40% of the business and are in there long term.|
|Where Next For Spire Healthcare Group PLC After Today’s Results?
By Motley Fool | Fri, 21st August 2015 - 11:23
Hospital group Spire Healthcare Group (LSE:SPI) has led the FTSE laggards in end-of-week business and was last dealing 12.9% lower from Thursday's close. Today's weakness puts to an end the recent bull run that has seen the stock advance almost a quarter since the end of June, an advance that saw the firm print record peaks of 401.6p per share just yesterday.
So what's going on?
Spire's insipid performance today has been prompted by half-year results that missed forecasts. The health specialists saw underlying revenues advance 5% during January-June, to £449.8m, a result that helped Spire swing to a pre-tax profit of £39.4m from a loss of £1.7m a year earlier.
Added to this, Spire spooked investors by announcing that "because of recent actions taken in response to the NHS Trusts' estimate of aggregate deficits for 2015/16, we recognise that there may be some near-term weakness in NHS demand over the remainder of this financial year."
And these problems have already begun to seep into activity at Spire by the looks of things. Total NHS sales advanced 14.1% during the first half, a performance that Investec describes as disappointing -- the broker noted that "we expected strong volumes as waiting lists were cleared ahead of the election, but these do not appear to have materialised."
Spire now expects demand from NHS customers to flatline in the second half of the year, forcing the business to downgrade its full-year revenues and earnings growth forecasts to between 4% and 6%. Previously Spire said that it expected to enjoy "mid to single digit" expansion in 2015.
So what next?
Still, Spire remains bullish over the potential of its its NHS division and commented that "the medium-to-long term trends in this business remain very positive," adding that demand from PMI and self-pay customers continues to surge higher.
Indeed, the result of financial constraints on NHS waiting lists at present time could push the number of private patients coming through Spire's doors, the company noted.
Naturally today's announcement is likely to lead to hefty earnings downgrades across the City. But for many today's hefty fall could represent a fresh buying opportunity -- the company's expansion scheme remains on track and new hospitals in Manchester and Nottingham are due to open during the first quarter of 2017.
On top of this, Medicare's purchase of a 29.9% stake back in June should boost its potential in overseas markets, not to mention turbocharge cost reduction across the business. In my opinion Spire's long-term growth case remains a compelling one.|
|After the big fall, and looking closely at the current situation, I decided to get back in yesterday at just over £2.22.
if Medicare's are happy to pay £3.60 there had to be value at these levels.|